The global biopharmaceutical deal machine ran at record velocity in 2024. China’s out-licensing deal value hit an estimated $47 billion, […]

Every year, pharmaceutical companies forfeit billions in recoverable IP value not because their science failed, but because their patent strategy

Between 2025 and 2030, an estimated $200-300 billion in branded drug sales globally will lose patent protection. That figure covers

The average capitalized cost to develop a new drug now exceeds $2.23 billion. The effective market exclusivity that investment buys,

The loss of exclusivity for a blockbuster biologic is no longer a theoretical risk management exercise. It is a discrete,

Every year, pharmaceutical companies quietly authorize hundreds of millions of dollars in new formulation work before a single press release

The Bayh-Dole Act of 1980 is arguably the single most consequential piece of legislation in the history of American biomedical

The Hatch-Waxman Act was supposed to make generic pharmaceuticals a reliable business. File an Abbreviated New Drug Application (ANDA), prove

The ‘grand bargain’ of pharmaceutical patents is one of the most consequential, most contested, and most misunderstood arrangements in modern